The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis

Conclusion: Signaling through Akt is important for survival of clonogenic cells in NCM, and omipalisib treatment as a monotherapy or in combination with MEK162 could be an effective therapeutic strategy to inhibit clonogenic growth.

Source: Cancer Genomics and Proteomics - July 5, 2018 Category: Cancer & Oncology Authors: BASU, D., SALGADO, C. M., BAUER, B., KHAKOO, Y., PATEL, J. R., HOEHL, R. M., BERTOLINI, D. M., ZABEC, J., BRZOZOWSKI, M. R., REYES-MUGICA, M. Tags: Article Source Type: research